Medically reviewed by Hemal Patel, PhD, Professor of Anesthesiology at UC San Diego School of Medicine. UCSD profile.
There is a slightly awkward truth at the centre of preventative testing in Britain. The NHS does many things extremely well, but it is not designed to provide broad private-style wellness panels for people who feel fine and would simply like a clearer baseline.
That is not negligence. It is rationing by evidence and need. NHS blood tests are usually ordered because there are symptoms, known risk factors, abnormal examination findings, or a defined screening programme. If you are broadly well, reasonably functional, and merely trying to spot trouble earlier, you will often find that the tests you had in mind are either unavailable, inconsistently offered, or only done after something else has already gone wrong.
The gap is real. The more useful question is what actually sits inside it.
Why the gap exists in the first place
The NHS works at population scale. That means its screening programmes need to show clear net benefit, reasonable cost-effectiveness, and acceptable rates of false positives and downstream harm. The UK National Screening Committee applies this logic for a reason. Screening sounds harmless until you remember that unnecessary testing can create anxiety, overdiagnosis and extra procedures with little gain.[1]
That is why routine NHS prevention tends to focus on established, high-yield pathways such as blood pressure, smoking status, diabetes risk, cholesterol, cervical screening, bowel screening, and similar population-level interventions. The NHS Health Check is useful, but it is narrow by design. It is mainly a cardiovascular risk screen for adults aged 40 to 74 in England, not a full metabolic or longevity work-up.[2]
Which preventative tests are commonly outside routine NHS care
This is where people get mildly irritated. A prevention-minded patient may reasonably want more detail than standard screening provides, but that does not automatically create an NHS indication.
Tests that are often not routinely offered without a specific reason include:
- Apolipoprotein B (ApoB). Increasingly discussed in lipidology, but still not a standard NHS screening marker for otherwise well adults.
- Lipoprotein(a), or Lp(a). Important in inherited cardiovascular risk, yet often checked only selectively despite guidance arguing for at least once-in-a-lifetime measurement in some settings.[3]
- Fasting insulin. Useful for metabolic context, but not part of routine NHS screening for well people.
- hs-CRP. A low-grade inflammation marker that can be interesting, though not especially specific.
- Homocysteine. Sometimes relevant, rarely standard for broad prevention.
- Expanded micronutrient or functional panels. Usually not done unless deficiency, malabsorption or another clinical issue is suspected.
- Specialist mitochondrial or cellular function style assessments. These sit firmly in the private domain rather than mainstream NHS preventive care.
To be clear, “not routinely offered” is not the same as “medically essential.” Some private providers blur that distinction because drama sells. The sober view is that some extra markers can sharpen risk assessment, while others are merely interesting until interpreted alongside symptoms, family history and follow-up action.
Cardiovascular risk is where the NHS-private difference is most obvious
If there is one area where private testing can add practical value, it is often cardiovascular refinement. The NHS will usually look at standard cholesterol measures within the context of overall risk. That is sensible and evidence-based. But it may not always explore particle-related risk markers such as ApoB or inherited markers such as Lp(a) in a person who feels well and does not obviously trigger further work-up.
That matters because atherosclerotic risk does not always announce itself politely. European and international guidance has increasingly given more attention to Lp(a) and ApoB in risk stratification.[3][4] In plain English, two people can look fairly similar on a basic lipid panel and still differ meaningfully once you look deeper.
This is one reason some people choose private testing. Not because the NHS is deficient, but because standard public-health screening and personalised risk curiosity are not the same thing.
Metabolic and inflammation markers often sit in the grey zone
The same applies to metabolic health. HbA1c is widely used and valuable. Fasting glucose is common. But broader prevention-minded questions often go further. What about fasting insulin? What about a more detailed view of low-grade inflammation? What if someone wants to establish a metabolic baseline before symptoms appear, particularly if they have a strong family history, central adiposity, poor sleep, or a suspicion that things are heading in the wrong direction?
The NHS may test further when the clinical picture justifies it. What it generally does not do is run broad exploratory panels simply because a patient would like a dashboard. Again, that is understandable. It just means private testing occupies the territory between “not ill enough for investigation” and “would still prefer not to wait for disease to become obvious.”
When private testing is actually sensible
Private testing is most useful when it answers a clear question. Examples include:
- There is a strong family history of early cardiovascular disease.
- You have borderline standard results and want a more detailed baseline.
- You are making meaningful changes to diet, training, weight, sleep or alcohol intake and want before-and-after comparison.
- You want a more detailed picture of mitochondrial or metabolic resilience than standard screening offers.
If that is your use case, extra data may be worthwhile. MeScreen’s own framing sits here. The aim is not to replace your GP, but to offer structured insight into biological function that can complement ordinary care. If you want context first, the How MeScreen works page and the scientific studies section are the places to start.
When private testing is not especially sensible
It is probably not sensible if you are collecting biomarkers the way some people collect limited-edition trainers. More numbers are not automatically more insight. A non-specific abnormality can generate unnecessary anxiety, and weak interpretation can lead to a pile of supplements nobody needed.
It is also poor value if there is no plan for what happens next. Good prevention is not about admiring a PDF. It is about deciding whether the result changes behaviour, repeat testing, or medical follow-up.
Where MeScreen fits in the prevention gap
For UK patients interested in cellular health, the private value proposition is not that the NHS has failed them. It is that public healthcare and personalised prevention solve different problems. The NHS is there to diagnose, treat and screen where the evidence supports doing so at scale. A test like MeScreen is aimed at people who want earlier visibility into function and risk, particularly around mitochondrial and broader cellular health, before problems become more obvious.
That only works if the output is clinically literate and grounded. No inflated “bio-age panic”, no Silicon Valley cosplay, no nonsense about becoming immortal by Tuesday. Just a better baseline, clearer interpretation, and a reasoned next step. If that sounds useful, you can review the MeScreen mitochondrial function test and compare it with the broader educational material in the mitochondrial health hub.
Medically reviewed by Hemal Patel, PhD
Professor of Anesthesiology at UC San Diego School of Medicine, with research interests in mitochondrial biology, caveolin signalling and cellular bioenergetics.
Read Hemal Patel's MeScreen reviewer profile · Verify on UCSD Profiles
The NHS is not meant to be a private prevention lab.
That leaves a legitimate gap. The trick is filling it with testing that is measured, evidence-aware and useful enough to change a decision.
Frequently asked questions
Does the NHS offer broad preventative blood testing if I feel well?
Usually no. The NHS generally tests when there are symptoms, risk factors, abnormal findings or a specific clinical reason. It does run screening programmes, but broad private-style prevention panels are not standard practice.
Is an NHS Health Check the same as a private longevity panel?
No. An NHS Health Check focuses mainly on cardiovascular risk in eligible adults. Private panels often include extra markers such as ApoB, Lp(a), fasting insulin, inflammatory markers and other functional measures.
Which private tests can be useful in the prevention gap?
That depends on context, but common examples include ApoB, lipoprotein(a), fasting insulin, hs-CRP and broader metabolic panels when these are not otherwise being checked through routine NHS care.
Should private testing replace my GP?
No. Private testing can add information, but it should not replace NHS care or proper clinical assessment. Concerning results still need interpretation in context, often with your GP or another qualified clinician.
References
- UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. GOV.UK. Available at: https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-programmes
- NHS. NHS Health Check. Available at: https://www.nhs.uk/tests-and-treatments/nhs-health-check/
- European Atherosclerosis Society. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361.
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Physiological bases for the superiority of apolipoprotein B over LDL cholesterol and non-HDL cholesterol as a marker of cardiovascular risk. J Am Heart Assoc. 2022;11:e025858.